About larimar therapeutics - LRMR
Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. It also engages in the research, development, and commercialization of novel therapeutics for mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
LRMR At a Glance
Larimar Therapeutics, Inc.
Three Bala Plaza East
Bala Cynwyd, Pennsylvania 19004
| Phone | 1-844-511-9056 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -165,673,000.00 | |
| Sector | Health Technology | Employees | 71 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LRMR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.066 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.849 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.028 |
LRMR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,333,422.535 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
LRMR Liquidity
| Current Ratio | 2.192 |
| Quick Ratio | 2.192 |
| Cash Ratio | 2.112 |
LRMR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -95.381 |
| Return on Equity | -132.593 |
| Return on Total Capital | -201.666 |
| Return on Invested Capital | -128.971 |
LRMR Capital Structure
| Total Debt to Total Equity | 5.208 |
| Total Debt to Total Capital | 4.951 |
| Total Debt to Total Assets | 2.777 |
| Long-Term Debt to Equity | 3.793 |
| Long-Term Debt to Total Capital | 3.606 |